After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.

Even though RGTI stock has already seen an impressive 1,300% increase over the past twelve months, the question persists: ...

The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.

The S&P 500 ticked 0.1% on Monday, July 14, 2025, as trade policy remained in the spotlight to kick off a week that also ...

The S&P 500 slid 0.3% on Friday, July 11, 2025, retreating from record levels after President Trump announced a 35% tariff on ...

Troubled REIT ARE shows massive upside potential with strong fundamentals and returns. Click for more on ARE stock and why it ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...